Answers are grounded in this paper and cite their sources.
Nivolumab, recently proven in a phase 3 clinical trial (CheckMate 901) to enhance survival when combined with gemcitabine-cisplatin for advanced urothelial carcinoma. This study aimed to assess its cost-effectiveness against gemcitabine-cisplatin alone, from US and Chinese payers' perspectives.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: